{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '45', 'Version Date: 07/22/2019', '9.6 SECOND MALIGNANCY', 'A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a', 'metastasis from the initial malignancy). Second malignancies require ONLY routine reporting', 'unless otherwise specified.', '10 NIH INTRAMURAL RESEARCH PROGRAM REPORTING', '10.1 DEFINITIONS', 'Please refer to definitions provided in Policy 801: Reporting Research Events found here.', '10.2 OHSRP OFFICE OF COMPLIANCE AND TRAINING/ IRB REPORTING', '10.2.1 Expedited Reporting', 'Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy', '802 Non-Compliance Human Subjects Research found here. Note: Only IND Safety Reports that', 'meet the definition of an unanticipated problem will need to be reported per these policies.', '10.2.2 IRB Requirements for PI Reporting at Continuing Review', 'Please refer to the reporting requirements in Policy 801: Reporting Research Events found here.', '10.3 NCICLINICAL DIRECTOR REPORTING', 'Problems expeditiously reported to the OHSRP/IRB in iRIS will also be reported to the NCI', 'Clinical Director. A separate submission is not necessary as reports in iRIS will be available to', 'the Clinical Director.', 'In addition to those reports, all deaths that occur within 30 days after receiving a research', 'intervention should be reported via email to the Clinical Director unless they are due to', 'progressive disease.', 'To report these deaths, please send an email describing the circumstances of the death to Dr.', 'Dahut at NCICCRQA@mail.nih.gov within one business day of learning of the death.', '11 STUDY OVERSIGHT AND DATA REPORTING/REGULATORY', 'REQUIREMENTS', '11.1 STUDY OVERSIGHT', 'This protocol is monitored at several levels, as described elsewhere in this section. The Protocol', 'Principal Investigator is responsible for monitoring the conduct and progress of the clinical trial,', 'including the ongoing review of accrual, patient-specific clinical and laboratory data, and routine', 'and serious adverse events; reporting of expedited adverse events; and accumulation of reported', 'adverse events from other trials testing the same drug(s). The Protocol Principal Investigator and', 'statistician have access to the data at all times.']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '46', 'Version Date: 07/22/2019', 'All Study Investigators at participating sites who register/enroll patients on a given protocol are', 'responsible for timely submission of data via the mechanism described elsewhere in this section.', \"All studies are also reviewed in accordance with the enrolling institution's data safety monitoring\", 'plan.', 'End of study procedures: Data will be stored according to HHS, FDA regulations, and NIH', 'Intramural Records Retention Schedule as applicable.', 'Loss or destruction of data: Should we become aware that a major breach in our plan to protect', 'subject confidentiality and trial data has occurred, this will be reported expeditiously per', 'requirements in section 10.2.1.', '11.2 DATA REPORTING', 'Data collection for this study will be done exclusively through Medidata Rave. Access to the', 'trial in Rave is granted through the iMedidata application to all persons with the appropriate', 'roles assigned in the Regulatory Support System (RSS). To access Rave via iMedidata, the site', 'user must have an active CTEP IAM account (https://eapps-ctep.nci.nih.gov/iam) and the', 'appropriate Rave role (Rave CRA, Read-Only, or Site Investigator) on either the Corresponding', 'Organization or Participating Organization roster at the enrolling site.', 'Upon initial site registration approval for the study in RSS, all persons with Rave roles assigned', 'on the appropriate roster will be sent a study invitation e-mail from iMedidata. To accept the', 'invitation, site users must log into the Select Login (https://login.imedidata.com/selectlogin', 'using their CTEP-IAM user name and password, and click on the \"accept\" link in the upper', 'right-corner of the iMedidata page. Please note, site users will not be able to access the study in', 'Rave until all required Medidata and study specific trainings are completed. Trainings will be in', 'the form of electronic learnings (eLearnings), and can be accessed by clicking on the link in the', 'upper right pane of the iMedidata screen.', 'Users that have not previously activated their Medidata/Rave account at the time of initial site', 'registration approval for the study in RSS will also receive a separate invitation from iMedidata', 'to activate their account. Account activation instructions are located on the CTSU website, Rave', 'tab under the Rave resource materials (Medidata Account Activation and Study Invitation', \"Acceptance). Additional information on iMedidata/Rave is available on the CTSU members'\", 'website under the Rave tab or by contacting the CTSU Help Desk at 1-888-823-5923 or by e-', 'mail at ctsucontact@westat.com.', '11.2.1 Method', 'This study will be monitored by the Clinical Trials Monitoring Service (CTMS). Data will be', 'submitted to CTMS at least once every two weeks via Medidata Rave (or other modality if', 'approved by CTEP). Information on CTMS reporting is available at:', '  http://www.theradex.com/clinicalTechnologies/?National-Cancer-Institute-NCI-1 On-site', 'audits will be conducted on an 18-36 month basis as part of routine cancer center site visits.', 'More frequent audits may be conducted if warranted by accrual or due to concerns regarding', 'data quality or timely submission. For CTMS monitored studies, after users have activated their', 'accounts, please contact the Theradex Help Desk at (609) 799-7580 or by email at', 'CTMSSupport@theradex.com for additional support with Rave and completion of CRFs.']\n\n###\n\n", "completion": "END"}